Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 1;97(6):833-838.
doi: 10.1002/ajh.26527. Epub 2022 Mar 21.

Checkpoint inhibitor immunotherapy during pregnancy for relapsed-refractory Hodgkin lymphoma

Andrew M Evens  1   2 , Justin S Brandt  2 , Cody J Peer  3 , Tyler Yin  3 , Dale Schaar  1 , Faheem Farooq  1 , Brett Mozarsky  3 , William D Figg  3 , Elad Sharon  4
Affiliations

Checkpoint inhibitor immunotherapy during pregnancy for relapsed-refractory Hodgkin lymphoma

Andrew M Evens et al. Am J Hematol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Andrew M. Evens: Advisory Board (research related): Seattle Genetics, MorphoSys, Karyopharm, Novartis, Pharmacyclics, Abbvie, and Epizyme; all other authors: none.

Figures

FIGURE 1
FIGURE 1
Imaging. (A) CT at 25 weeks gestation of right lower lobe mass measuring 4.5 × 2.4 cm and left lower lobe mass measuring 4.3 × 3.2 cm; (B) CT at 25 weeks gestation with axial view of extensive retroperitoneal and pelvic lymphadenopathy, and gravid uterus; (C) CT at 25 weeks gestation of conglomerate of para‐aortic lymphadenopathy in the upper abdomen with necrotic features measuring approximately 11 × 4.4 cm; (D) CT chest at 32 weeks gestation of right infrahilar location smaller measuring 2.3 × 3.2 cm, and left lower lobe parenchymal mass measured 3.6 × 3.1 cm; (E) MRI abdomen at 32 weeks gestation of axial view of smaller retroperitoneal mass; (F) MRI abdomen at 32 weeks gestation of left sided para‐aortic lymphadenopathy smaller measuring 8.3 × 6.0 × 5.3 cm; (G) PETCT coronal view at 2 weeks postnatal of right lower lobe perihilar opacity measuring 2.2 cm; redemonstration of left renal hilar mass; (H) Coronal re‐formatted PET/CT image at 2 weeks postnatal; and (I) PET/CT at 2 weeks postnatal of fused coronal view with decrease in size of left renal hilar mass at 4.1 cm with low‐level SUV max 1.5. CT, Computerized tomography; MRI, magnetic resonance imaging; PET, positron emission tomography [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 2
FIGURE 2
Observed and simulated nivolumab serum concentrations. The observed concentrations measured in serum obtained from maternal peripheral blood (predose, green; postdose, blue) and the umbilical cord blood (red dot) were overlaid on simulated serum concentration versus time following a 240 mg every 2‐week regimen (median [90% prediction interval], black line [shaded region]). The patient underwent spontaneous labor 6 days following the sixth nivolumab dose. The observed data from the mother were very close to the median expected values. The umbilical cord concentrations indicated nivolumab was able to cross the blood‐placental barrier. No nivolumab was detected in the placental tissue [Color figure can be viewed at wileyonlinelibrary.com]
See this image and copyright information in PMC

References

    1. Van Calsteren K, Heyns L, De Smet F, et al. Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J Clin Oncol. 2010;28:683‐689. - PubMed
    1. Dunleavy K, McLintock C. How I treat lymphoma in pregnancy. Blood. 2020;136:2118‐2124. - PubMed
    1. Evens AM, Advani R, Press OW, et al. Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. J Clin Oncol. 2013;31:4132‐4139. - PubMed
    1. Lishner M, Avivi I, Apperley JF, et al. Hematologic malignancies in pregnancy: management guidelines from an international consensus meeting. J Clin Oncol. 2016;34:501‐508. - PubMed
    1. Saliba AN, Xie Z, Higgins AS, et al. Immune‐related hematologic adverse events in the context of immune checkpoint inhibitor therapy. Am J Hematol. 2021;96:E362‐E367. - PubMed

Substances